Omega-3 polyunsaturated fatty acids reduce kidney aging and fibrosis through a receptor called FFAR4, which activates cellular regeneration pathways in tubular cells. FFAR4 expression declines with age and in chronic kidney disease patients, and restoring its signaling mitigates senescence and fibrotic progression.
Key Points
- FFAR4 expression declines in aging and CKD kidneys
- Omega-3 activation via FFAR4 reduces tubular cell senescence
- FFAR4 suppresses kidney fibrosis through intercellular signaling
Longevity Analysis
Kidney function decline is a primary driver of aging-related mortality and morbidity. The identification of FFAR4 as a molecular brake on renal senescence—and its downstream activation of Klotho, a well-established longevity marker—positions omega-3 therapy as a direct intervention against tissue aging at the cellular level. The mechanism reveals how a targeted nutritional signal can reverse degenerative signaling patterns in epithelial cells and suppress the fibroblast activation that perpetuates organ-level decline. This distinguishes omega-3 supplementation from broad anti-inflammatory approaches by showing tissue-specific, receptor-mediated restoration of regenerative capacity rather than systemic immune suppression.
Original published by Wiley Aging Cell, by Letian Yang, Lei Tang, Jian Li, Dekai Liu, Chunchun Hu, Fan Guo, Lin Lin, Rongshuang Huang, Ping Fu, Liang Ma .